Key Takeaways
- India’s economy has seen a 55% growth in per capita GDP between 2014 and 2023, with an expected annual growth rate of at least 6%.
- The National Stock Exchange of India has surpassed $4 trillion in market capitalization, becoming the sixth largest stock market globally.
- Innovations in biotechnology are being emphasized by the Indian government with a goal of establishing India as a major player in the global biologics market by 2025.
Economic Growth and Infrastructure Development
India’s economy continues to thrive, boasting a 55% increase in per capita GDP from 2014 to 2023. Analysts forecast a sustained annual growth rate of no less than 6%. The country’s public digital infrastructure investments, particularly a QR-code based Unified Payments Interface, are making cash transactions nearly obsolete, positioning India ahead of both Europe and the United States in digital advancements.
In addition to digital infrastructure, substantial investments in traditional infrastructure — including roads, ports, and airports — are underway. The Modi government has launched incentive programs valued at approximately $26 billion to attract investments, particularly in the pharmaceutical sector.
Focus on Biotechnology
The Indian government has identified biotechnology as a vital sector for economic growth. The National Biotechnology Development Strategy for 2020–2025 aims to harness biotechnology for national development, aspiring to create a $150 billion bioeconomy by 2025. Initiatives include supportive policies, workforce training, and the establishment of biomanufacturing zones to make India a competitive global player.
India has been gradually building its presence in biologics outsourcing, with drug-discovery and contract research organization (CRO) services concentrated in Hyderabad and Bengaluru. These regions are now advancing into chemistry, manufacturing, and controls (CMC) development and services.
Key Players in the Biologics Market
Leading the charge is Syngene International, a key player in biologics and CGMP manufacturing. It recently acquired a large-scale facility for mammalian cell-culture manufacturing in Bengaluru, originally set up for the Sputnik adenoviral COVID-19 vaccine.
Aurigene Pharmaceutical Services, part of Dr. Reddy’s Laboratories, aims to become a significant contender in biologics by leveraging its extensive experience and new facilities dedicated to drug-substance and drug-product manufacturing.
Other notable players include GVK Industries, which has rebranded its biologics operations under Aragen, and Enzene Biosciences, a subsidiary of Alkem Laboratories, which is expanding its biologics capabilities with new facilities. Established companies like Kemwell Biopharma and Stelis Biopharma also contribute to the growing biomanufacturing landscape in India, each offering varying levels of contract development and manufacturing organization (CDMO) services.
India’s commitment to innovation in biotechnology and biologics positions it as an emerging hub in the global market, shaping the future of health and biomanufacturing.
The content above is a summary. For more details, see the source article.